

1, SEQ ID NO: 2, SEQ ID NO: 3 or at least one analyte thereof related to said disease state; and
means for determining binding between said biochemical material and said biomolecule;
whereby at least one analysis to determine a presence of a marker, analyte thereof, or a
biochemical material specific thereto, is carried out on a sample.

Claim 29. Polyclonal antibodies produced against a marker sequence ID selected from the
group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or at least one analyte thereof
in at least one animal host.

Claim 30. An antibody that specifically binds a biopolymer including a marker selected
from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 or at least one
analyte thereof.

Claim 33. A process for identifying therapeutic avenues related to a disease state
comprising:

conducting an analysis as provided by the kit of claim 18; and
interacting with a biopolymer selected from the group consisting of SEQ ID NO: 1, SEQ ID
NO: 2, SEQ ID NO: 3 or at least one analyte thereof;
whereby therapeutic avenues are developed.

Claim 34. The process for identifying therapeutic avenues related to a disease state in
accordance with claim 33, wherein said therapeutic avenues regulate the presence or absence of the